<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02192099</url>
  </required_header>
  <id_info>
    <org_study_id>GLYX13-C-203</org_study_id>
    <nct_id>NCT02192099</nct_id>
  </id_info>
  <brief_title>Open Label Extension for GLYX13-C-202, NCT01684163</brief_title>
  <official_title>Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in
      GLYX13-C-202.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in
      GLYX13-C-202 in an open label extension trial.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 8, 2014</start_date>
  <completion_date type="Anticipated">October 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HDRS-17 to end of participation</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>GLYX-13 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Dose of GLYX-13</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLYX-13 10 mg/kg</intervention_name>
    <description>Intravenous administration of 10 mg/kg into arm. Can be adjusted to 5 mg/kg weekly or biweekly.</description>
    <arm_group_label>GLYX-13 10 mg/kg</arm_group_label>
    <other_name>GLYX-13 IV Dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants who have completed 8 weeks of treatment in the preceding study
             (GLYX13-C-202, NCT01684163.

          2. Participants who wish to continue treatment with GLYX-13 after the preceding study.

          3. Meets Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR)
             criteria for major depressive disorder (MDD).

          4. Female subjects of childbearing potential with a negative serum pregnancy test prior
             to entry into the study and who are practicing an adequate method of birth control (eg
             oral or parenteral contraceptives, intrauterine device, barrier, abstinence) and who
             do not plan to become pregnant during the course of the study. Female subjects may be
             included without a negative serum pregnancy test if they are surgically sterile or at
             least 2 years post-menopausal.

          5. Clinical laboratory values &lt;2 times the upper limit of normal (ULN) or deemed not
             clinically significant per the investigator and Naurex medical monitor.

          6. Ability to understand the requirements of the study, provide written informed consent,
             abide by the study restrictions, and agree to return for the required assessments.

          7. Based on the investigator and Naurex medical monitor's clinical judgment, subjects
             with eating disorders, obsessive compulsive disorder (OCD), panic disorder,
             post-traumatic stress disorder (PTSD), and generalized anxiety disorders secondary to
             major depressive episodes (MDEs) are permitted.

        Exclusion Criteria:

          1. Axis I diagnosis of delirium, dementia, dysthymia, amnestic or other cognitive
             disorder, schizophrenia or other psychotic disorder, bipolar I or II disorder, eating
             disorder (anorexia or bulimia nervosa), obsessive-compulsive disorder, panic disorder,
             acute stress disorder, agoraphobia, social phobia, attention-deficit hyperactivity
             disorder (ADHD), or PTSD.

          2. A clinically significant current Axis II diagnosis of borderline, antisocial,
             paranoid, schizoid, schizotypal, or histrionic personality disorder

          3. Experiencing hallucinations, delusions, or any psychotic symptomatology in the current
             episode; lifetime history of psychosis.

          4. Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, or a history of seizures
             or strokes.

          5. Currently hospitalized or residing in an in-patient facility during study
             participation.

          6. Substance abuse since the end of participation in GLYX13-C-202, including greater than
             or equal to 5 units of alcohol per day where 1 unit = Â½ pint of beer, 1 glass of wine
             4 oz, or 1 oz. of spirits consumed most weeks or in the opinion of the investigator

          7. Women who are planning to become pregnant during the course of the study.

          8. Allergy or intolerance to current antidepressant or other current medications.

          9. Participation in any clinical trial of an investigational product or device within 30
             days of enrollment in this trial with the exception of GLYX13-C-202.

         10. Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid or other
             agent that in the opinion of the investigator is being abused

         11. Pose current (past 6 months) suicide risk based on administration of the C SSRS and
             the investigator's clinical judgment.

         12. Human immunodeficiency virus (HIV) infection (based on the based on the HIV-1 &amp; HIV-2
             antibody screen) or other ongoing infectious disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raffaele Migliore</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Office of Psychiatric Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas School of Medicine Clinical Trial Unit</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmaSite Research, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials Inc.</name>
      <address>
        <city>Roslindale</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodlands Professional Princeton Medical Institute Building</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finger Lake Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindner Center of HOPE</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences Phase 2/3 Outpatient &amp; CNS Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

